Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.

Najjar, AbdulkarimPunt, AnsWambaugh, JohnPaini, AliciaEllison, CorieFragki, StylianiBianchi, EnricaZhang, FagenWesterhout, JoostMueller, DennisLi, HequnShi, QuanGant, Timothy WBotham, PhilBars, RémiPiersma, Aldertvan Ravenzwaay, BenKramer, Nynke I2022-09-122022-09-122022-09-053606317310.1007/s00204-022-03356-5http://hdl.handle.net/10029/626082en© 2022. The Author(s).IVIVENAMsPBK modelsRegulatory acceptanceRisk assessmentTowards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.Article1432-0738Archives of toxicology 2022; 96(12):3407-3419